
    
      This multi-national, multi-center study is a double blind, randomized, placebo-controlled
      trial with 2 parallel treatment arms (1 active, 1 placebo) to assess the conversion efficacy
      and safety of 2 intravenous doses of RSD1235 in subjects with atrial fibrillation or atrial
      flutter following valvular and/or coronary artery bypass graft (CABG) surgery.
    
  